Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11704

    +

    P2.10-012 - Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer (ID 943)

    09:30 - 09:30  |  Author(s): S. Igawa
    • Abstract

    Background
    Currently, there are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line or further line therapy. Previous studies of amrubicin in patients with previously untreated advanced NSCLC in succession demonstrated an overall response rate of 18.3-27.9%, and a median survival time of 8.2-9.8 months. Accordingly, amrubicin was equivalent to anticancer agents such as taxanes, gemcitabine, vinorelbine, and pemetrexed in terms of single-agent activity against NSCLC. The purpose of this study was to evaluate the efficacy of amrubicin monotherapy as a salvage treatment in heavily pretreated NSCLC patients.

    Methods
    The records of NSCLC patients who received amrubicin monotherapy as a third or later line of chemotherapy at a Kitasato University Hospital between January 2009 and December 2012 were retrospectively reviewed. Amrubicin was administered to patients by intravenous injection in a dose of 35 mg/m[2] or 40 mg/m[2] daily on 3 consecutive days, and cycles were repeated at 3-week intervals.

    Results
    There were 36 patients who met the inclusion criteria. Their median number of prior chemotherapy was 4 (range: 2 to 7), and the median number of cycles of chemotherapy per patient was 4 (range: 1 to 9). Grade 3 or 4 hematologic toxicities included neutropenia (61.1%), leukopenia (58.3%), thrombocytopenia (22.2%), and anemia (11.1%). Febrile neutropenia occurred in 8 patients (22.2%). Non-hematologic toxicities were mild. Treatment related death was not observed. The overall response rate, median progression-free survival time, and median survival time were 8.3%, 1.7 months, and 6.3 months, respectively. Progression-free survival time was the same, 1.7 months, in both the 35 mg/m[2] dose group and the 40 mg/m[2] dose group.Figure 1Figure 2

    Conclusion
    Amrubicin exhibits modest activity and acceptable toxicity when used as a third or later line of chemotherapy for advanced NSCLC.